Drug General Information (ID: DDISOJW21V)
Drug Name			Droperidol		Drug Info		Panitumumab		Drug Info
Drug Type		Small molecule				Monoclonal antibody
Therapeutic Class		Antipsychotic Agents				Antineoplastics

Mechanism of Droperidol-Panitumumab Interaction (Severity Level: Major)
Increased risk of ventricular arrhythmias Click to Show/Hide Mechanism Graph
Drug Name		Droperidol				Panitumumab
Mechanism		Prolong QT interval				Hypomagnesemia
Key Mechanism Factor 1
		Factor Name		Ventricular arrhythmias
		Factor Description		Ventricular arrhythmias are abnormal heart rhythms that cause your heart's lower chambers to pump blood instead of pumping it. This can limit or stop your heart from supplying blood to your body. While some of these arrhythmias are harmless and do not cause symptoms, others can have serious, even fatal, effects on your body.
Mechanism Description		Increased risk of ventricular arrhythmias by the combination of Droperidol and Panitumumab

Recommended Action
Management		The manufacturer recommends extreme caution if droperidol must be given concomitantly with these agents. The dosage of droperidol should be individualized and titrated to the desired effect. Routine vital sign and ECG monitoring is recommended. When droperidol is used in combination with other drugs that cause CNS and/or respiratory depression, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.

References
1	Canadian Pharmacists Association.
2	Cerner Multum, Inc. "Australian Product Information.".
3	Cerner Multum, Inc. "UK Summary of Product Characteristics.".
4	Glassman AH, Bigger JT Jr "Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death." Am J Psychiatry 158 (2001): 1774-82. [PMID: 11691681]
5	Product Information. Inapsine (droperidol). Janssen Pharmaceutica, Titusville, NJ.
6	EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring.".